What Is Alectinib (Alecensa)? FDA Approval, Turkish Authorization and Reimbursement Status
In this article
What is alectinib (Alecensa)? Drug profile, ALINA and ALEX data, Turkish authorization and price
Alectinib is a drug used for ten years in ALK-positive lung cancer and remains a cornerstone of first-line treatment today. But its real importance lies elsewhere: it is the first and only targeted therapy approved for surgically removed early-stage ALK-positive lung cancer. In the ALINA trial, it reduced the risk of recurrence or death to one-quarter (hazard ratio 0,24). This article brings together the complete drug profile, early-stage and metastatic data, side effects with their rates, the dose-reduction schedule, authorization–reimbursement–pricing in Turkey, and options after alectinib.
| Active ingredient | Alectinib |
| Brand name | ALECENSA (the same in Turkey and the United States) |
| Marketing authorization holder (Turkey) | Roche Müstahzarları Sanayi A.Ş. |
| Manufacturer | Genentech / Roche — imported from Switzerland |
| Class | Second-generation ALK tyrosine kinase inhibitor |
| ATC code | L01ED03 |
| Formulation | 150 mg hard capsule, box of 224 capsules |
| Standard dose | 600 mg 2 times daily — 4 capsules in the morning, 4 in the evening; 12 hours apart |
| Dose-reduction steps | 600 mg × 2 → 450 mg × 2 → 300 mg × 2; discontinue if 300 mg × 2 cannot be tolerated |
| Relationship to food | Must be taken with food — absorption drops markedly on an empty stomach |
| Approved indications | ALK-positive surgically treated early-stage and advanced/metastatic non-small cell lung cancer |
| Adjuvant treatment duration | Up to 2 years |
| Prescription status (Turkey) | Standard prescription; with a medical oncology specialist’s report |
| Date | Approval |
|---|---|
| 11 December 2015 | Accelerated approval for ALK-positive metastatic disease progressing after crizotinib |
| 6 November 2017 | First-line ALK-positive metastatic disease |
| 18 April 2024 | Postoperative (adjuvant) treatment — in ALK-positive patients with tumors of 4 cm or larger or lymph node involvement. This is the first and only targeted therapy approval in this setting |
Mechanism of Action
When the ALK gene joins another gene following a chromosome break (fusion), it produces a growth signal that remains permanently switched on; the cell continually receives the instruction to “divide.” By blocking this enzyme, alectinib switches off downstream pathways such as STAT3 and Akt and stops cell division.
Two technical details make a practical difference:
Active metabolite: M4
In the liver, CYP3A4 forms the M4 metabolite, which has potency similar to the parent molecule. Thus, the drug’s effect comes from the combined action of both molecules, rather than a single molecule.
Brain penetration
Alectinib is not a target of transporter systems that pump substances out of the brain (P-glycoprotein); it can therefore accumulate in the central nervous system. This is a crucial feature because ALK-positive disease very frequently spreads to the brain.
Dependence on food
Its oral absorption is approximately %37, and when taken with a high-fat meal, its blood level can rise up to threefold. This is not “take it with food if you wish”; it is a requirement for receiving the correct dose.
Early-Stage Disease: The ALINA Trial
ALINA compares 2 years of alectinib with standard platinum chemotherapy in completely resected ALK-positive lung cancer in a phase 3 trial (NCT03456076). Patient group: stage IB (tumor ≥4 cm) through stage IIIA, totaling 257 patients (130 versus 127).
hazard ratio
initial analysis
chemotherapy: %54,0
chemotherapy: %47,0
hazard ratio
| Endpoint | Initial analysis | 4-year update median follow-up 48 months |
|---|---|---|
| Disease-free survival (all patients) | Not reached vs 41,3 months HR 0,24 (0,13–0,43); p<0,001 |
Not reached vs 41,4 months HR 0,35 (0,23–0,54) |
| Disease-free at 2 years | %93,6 vs %63,7 | — |
| Disease-free at 3 years | %88,7 vs %54,0 | — |
| Disease-free at 4 years | — | %75,5 vs %47,0 |
| Stage II–IIIA subgroup | HR 0,24 (0,13–0,45) | HR 0,36 (0,23–0,56); at 4 years %74,5 vs %46,3 |
| Brain disease-free survival | HR 0,22 (0,08–0,58) At 2 years %98,4 vs %85,8 |
HR 0,37 (0,19–0,74) At 4 years %90,4 vs %76,1 |
| Overall survival | Immature (2 versus 4 events) | At 4 years %98,4 vs %92,4 HR 0,40 (0,12–1,32) — still immature |
Two things need to be considered together in this table. The hazard ratio of 0,24 in the initial analysis is of a magnitude rarely seen in adjuvant oncology—it means the risk of recurrence falls to one-quarter. However, with longer follow-up, the ratio increased to 0,35. This is expected: treatment ends at 2 years, after which some patients develop late recurrences. Thus, the question becomes— does alectinib prevent recurrence or delay it? The four-year data still show a strong difference (%75,5 versus %47,0), but how the curves will behave with longer follow-up is not yet known. Overall survival is also immature and will probably remain so for a long time.
The brain data are particularly important. ALK-positive lung cancer very frequently spreads to the brain, and in a patient who has undergone surgery, the brain is often the first site of recurrence. In ALINA, the hazard ratio for brain disease-free survival was 0,22; at the fourth year, among patients receiving alectinib, %90,4 had no brain recurrence (compared with %76,1 in the chemotherapy arm). Given that chemotherapy does not penetrate the brain, this difference is biologically expected as well.
Metastatic Disease: The ALEX Trial and Final Survival
ALEX compared alectinib with crizotinib in previously untreated ALK-positive metastatic disease (NCT02075840; 303 patients). The final overall survival analysis was presented at ESMO 2025, and the picture proved more complicated than expected.
| Alectinib | Crizotinib | |
|---|---|---|
| Median progression-free survival | 34,8 months | 10,9 months |
| HR 0,43 (0,32–0,58) | ||
| Median overall survival | 81,1 months (62,3–not reached) | 54,2 months (34,6–75,6) |
| HR 0,78 (0,56–1,08); p=0,132 — did not reach significance | ||
| 7-year overall survival | %48,6 | %38,2 |
| 5-year overall survival | %62,5 | %45,5 |
| Median duration of response | 42,3 months | 11,1 months (HR 0,41) |
| Median treatment duration | 28,1 months | 10,8 months |
| Survival in those with brain metastases at baseline | 63,4 months | 30,9 months (HR 0,68) |
81,1 months versus 54,2 months—approximately a 27-month difference—but not statistically significant. Why? For two reasons. The first is crossover: among patients in the crizotinib arm, %25,2 switched to alectinib after progression. Thus, the comparison was not between “receiving alectinib” and “not receiving it,” but between “receiving it from the start” and “receiving it later.” Second, the upper confidence limit was 1,08, meaning the “no difference” scenario remains compatible with the data.
The correct interpretation is: alectinib delays disease progression more than threefold, and this is undisputed; however, a survival extension has not been proven in a randomized comparison. Nevertheless, median overall survival reaching 81 months—approximately 7 years—is extraordinary for metastatic lung cancer.
Side Effects: With Rates
Contrary to common belief, alectinib’s side-effect profile does not resemble chemotherapy. The main findings are constipation, muscle pain, elevated liver tests and—the most common laboratory finding— elevated muscle enzyme (CPK). The following tables are presented separately for the early-stage (ALINA) and metastatic (ALEX) studies because the patient populations, and therefore the rates, differ.
| Side effect | Any grade | Grade 3–4 |
|---|---|---|
| Constipation | %42 | %0,8 |
| Muscle pain (myalgia) | %34 | %0,8 |
| Rash | %23 | %1,6 |
| Edema | %16 | %0 |
| Weight gain | %13 | %0,8 |
| Slowed heart rate (bradycardia) | %12 | %0 |
| Laboratory findings | ||
| Elevated CPK (muscle enzyme) | %77 | %8 |
| Elevated AST | %75 | %0,8 |
| Elevated bilirubin | %68 | %2,3 |
| Low hemoglobin | %69 | %0 |
| Elevated ALT | %57 | %2,3 |
| Elevated creatinine | %41 | %0 |
| Side effect | Any grade | Grade 3–4 |
|---|---|---|
| Constipation | %34 | %0 |
| Muscle pain | %23 | %0 |
| Edema | %22 | %0,7 |
| Rash | %15 | %0,7 |
| Renal impairment | %12 | %3,9 |
| Slowed heart rate | %11 | %0 |
| Laboratory findings | ||
| Anemia | %62 | %7 |
| Elevated bilirubin | %54 | %5 |
| Elevated AST | %50 | %6 |
| Elevated ALT | %40 | %6 |
| Elevated creatinine | %38 | %4,1 |
| Elevated CPK | %37 | %2,8 |
| Condition | Frequency | Action |
|---|---|---|
| Lung inflammation (ILD / pneumonitis) | %1,7 | Permanently discontinue the drug if it occurs at any grade |
| Hemolytic anemia | %3,1 | If anemia worsens, checking iron alone is insufficient; hemolysis should be investigated |
| Sensitivity to light (photosensitivity) | Common | Sun protection is essential — see below |
| Severe muscle pain and elevated CPK | Elevated CPK is very common | Measure CPK for unexplained muscle pain and weakness |
Hemolytic anemia is a less well-known but important warning for this drug. If hemoglobin falls in a patient taking alectinib, the initial reaction is usually “the cancer is progressing” or “iron deficiency.” However, in approximately %3 of patients, because of red blood cell breakdown, anemia may develop. The high frequency of elevated bilirubin (%54–68) also sometimes results from hemolysis rather than the liver. Without making this distinction, it may be mistakenly attributed to liver toxicity, leading to unnecessary treatment discontinuation.
| ALINA (adjuvant) | ALEX (metastatic) | |
|---|---|---|
| Dose interruption | %27 | %20–32 |
| Dose reduction | %26 | %17–23 |
| Permanent discontinuation due to side effects | %5 (in the chemotherapy arm %13) | %11–18 |
| Grade 3–4 side effect | %30 (chemotherapy %31) | %57,9 (crizotinib %57,6) |
The most meaningful comparison in ALINA is this: in the alectinib arm, the rate of treatment discontinuation due to side effects was %5 , while in the chemotherapy arm it was %13 . Grade 3–4 side-effect rates were almost identical (%30 versus %31), but treatment-related grade 3–4 events were markedly less common with alectinib (%18 versus %28). Thus, two years of tablets proved both more effective and easier to tolerate than four cycles of chemotherapy.
Caution When Reading the Tables: The percentages come from different sources and definitions. In ALINA, elevated CPK appears as a laboratory finding at %77, a reported adverse event at %43—this is not a contradiction but two different measurement methods. The rates of lung inflammation and hemolytic anemia come from the European product information’s pooled safety data, rather than ALINA or ALEX alone. We could not separately confirm ALINA-specific rates of photosensitivity, ILD and hemolytic anemia.
Dose Reduction and Management Schedule
| Level | Dose | Number of capsules |
|---|---|---|
| Starting dose | 600 mg 2 times daily | Morning 4 + evening 4 |
| 1st reduction | 450 mg 2 times daily | Morning 3 + evening 3 |
| 2nd reduction | 300 mg 2 times daily | Morning 2 + evening 2 |
| If not tolerated | Permanently discontinue | |
| Condition | Action |
|---|---|
| ALT/AST higher than 5 times normal, bilirubin ≤2 times normal | Interrupt; when below 3 times normal or back to baseline, resume at a reduced dose . |
| ALT/AST above 3 times normal and bilirubin above 2 times normal without biliary obstruction or hemolysis |
Permanently discontinue |
| Total bilirubin higher than 3 times normal | Interrupt; when below 1,5 times normal, resume at a reduced dose |
| Lung inflammation — any grade | Permanently discontinue |
| Symptomatic bradycardia | Interrupt until heart rate rises above 60. If another drug contributes, address it and resume at the same dose ; otherwise, at a reduced dose |
| Life-threatening bradycardia without a contributing drug | Permanently discontinue |
| CPK higher than 5 times normal | Interrupt until below 2,5 times normal; at the same dose resume |
| CPK above 10 times normal or a second elevation above 5 times normal | Interrupt until below 2,5 times normal; resume at a reduced dose |
| Grade 3 renal impairment (creatinine above 3 times normal) | Interrupt until below 1,5 times normal; resume at a reduced dose |
| Grade 4 renal impairment | Permanently discontinue |
Two rules are particularly important to remember. First: if lung inflammation occurs at any grade, permanently discontinue the drug —unlike many drugs, there is no “continue if mild” option. New-onset cough, shortness of breath and fever require immediate assessment. Second: a simultaneous rise in liver enzymes and bilirubin (ALT/AST >3 times normal and bilirubin >2 times normal) also requires permanent discontinuation—but hemolytic anemia and biliary obstruction must first be excluded, because this drug can cause elevated bilirubin for other reasons.
| Condition | Dose |
|---|---|
| Mild and moderate hepatic impairment | No adjustment required |
| Severe hepatic impairment (Child-Pugh C) | 450 mg 2 times daily |
| Mild and moderate renal impairment | No adjustment required |
| Severe renal impairment | European product information says “no adjustment required” (renal elimination is negligible); United States product information says “not studied”— this is a genuine difference in the texts |
Pharmacokinetics and Drug Interactions
| Parameter | Value |
|---|---|
| Oral absorption | %37; with a high-fat meal, blood levels increase up to 3-fold |
| Time to peak blood level | Approximately 4 hours |
| Plasma protein binding | Above %99 (both alectinib and M4) |
| Metabolic pathway | CYP3A4; the active metabolite M4 is formed |
| Elimination | Approximately %98 through feces ; urinary elimination is negligible |
Interactions. CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin) and grapefruitincrease alectinib blood levels and toxicity. CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital) and St. John’s wort reduce effectiveness. Concurrent use with drugs that slow the heart rate, such as beta blockers, certain calcium channel blockers and digoxin, also increases the risk of bradycardia—be sure to report if you take these drugs. Whenever starting a new medication, state that you are taking alectinib.
Authorization, Reimbursement and Price in Turkey
Authorization. ALECENSA is authorized in Turkey; the authorization holder is Roche Müstahzarları Sanayi A.Ş.. There are three approved indications in Turkey:
1. Adjuvant treatment in surgically treated early-stage disease: In patients with confirmed ALK positivity (demonstration of rearrangement/fusion by FISH, RT-PCR, next-generation sequencing or immunohistochemistry) at high risk of recurrence— stage IB (tumor ≥4 cm) through stage IIIA —following complete tumor resection. Treatment duration is up to 2 years.
2. First-line in advanced/metastatic disease: As a single agent in ALK-positive patients until progression.
3. After crizotinib: As a single agent until progression in ALK-positive patients with locally advanced or metastatic disease previously treated with crizotinib.
Could not be verified: The authorization date and number. During preparation of this article, titck.gov.tr could not be accessed; the indication text was taken from a third-party mirror of the Summary of Product Characteristics. The only reliable way to verify authorization and indication status in Turkey is to search titck.gov.tr/kubkt using the active ingredient name (“alektinib”).
SGK Reimbursement Status
Alectinib is covered by SGK, but reimbursement conditions are narrower than the authorization , and this difference matters in practice:
- First-line: ALK positivity confirmed by FISH testing in an accredited laboratory is required for coverage in advanced-stage patients as a single agent until progression.
- Second-line: Coverage is provided until progression in metastatic patients previously treated with crizotinib who developed progression and whose ALK positivity was confirmed by FISH.
- Prohibition on sequential use: In patients progressing after alectinib, sequential or combined use of crizotinib, brigatinib or ceritinib is not covered.
- Exception: Switching between alectinib, brigatinib and ceritinib solely because of an intolerable major side effect (grade 3–4) —if this is specified in the Ministry of Health’s off-label use approval—is not considered sequential use.
Two points require attention. First: the reimbursement text accepts only FISH testing for ALK positivity, whereas the authorization text also accepts RT-PCR, next-generation sequencing and immunohistochemistry. If diagnosis was made using NGS, additional confirmation may be needed at the reimbursement stage. Second: adjuvant (postoperative) use is not included in the reimbursement text —reimbursement for this authorized indication must be confirmed separately. Authorization and reimbursement are two separate processes; a drug’s authorization does not mean that SGK covers it.
Reimbursement rules change frequently. The text above reflects the conditions available to us when this article was prepared; the current Healthcare Implementation Communiqué (SUT) text and pharmacy practice must be confirmed separately.
Price and Cost per Cycle
| Product | Retail price | Note |
|---|---|---|
| ALECENSA 150 mg, 224 hard capsules | 108.391,73 ₺ | Barcode 8699505153407; valid as of September 2026 |
Price changes: Throughout 2026, the price fluctuated between 108.391,73 ₺ and 100.054,00 ₺ (in March 2026 it was briefly listed at 100.054,00 ₺, and from 31 March returned to 108.391,73 ₺). As of September 2026, the valid price is 108.391,73 ₺. As drug prices in Turkey are updated regularly, the calculation below is intended only to give an idea of the magnitude.
| Scenario | Daily dose | Required for 28 days | Boxes required | Approximate cost |
|---|---|---|---|---|
| Standard use adjuvant, first-line or after crizotinib — all the same |
600 mg × 2 8 capsules/day |
224 capsules | 1 box (covers the requirement exactly) | ≈ 108.392 ₺ |
| 1st dose reduction | 450 mg × 2 6 capsules/day |
168 capsules | 1 box (56 capsules left over) | ≈ 108.392 ₺ remaining capsules carry over to the next period |
| 2nd dose reduction | 300 mg × 2 4 capsules/day |
112 capsules | 1 box (112 capsules left over) | ≈ 108.392 ₺ one box covers two 28-day periods |
Alectinib’s packaging is among the most rational for drugs of this kind: 224 capsules cover exactly 28 days at the standard dose (8 × 28 = 224). There is neither excess nor shortage. With dose reduction, the box lasts longer and the actual cost falls—the remaining capsules carry over to the next period.
However: These are our own calculations, not official pricing. The figure given here is the drug’s listed price; a patient covered by SGK does not pay this amount. As adjuvant treatment lasts 2 years, the total drug quantity corresponds to approximately 26 boxes—a cost of around 2,8 million ₺ at today’s price.
How Is Alectinib Taken? Practical Information
- 4 capsules in the morning, 4 in the evening —approximately 12 hours apart, at the same times every day.
- Always take it with food. This is a requirement, not a preference: on an empty stomach, the amount of drug entering the bloodstream falls markedly. A meal containing fat best supports absorption.
- The capsules should be swallowed whole with plenty of water; do not open, crush or dissolve them in liquid.
- If a dose is missed, do not make it up; take the next dose at its usual time. If vomiting occurs after taking the drug, do not repeat the dose.
- Sun protection is essential. Alectinib causes photosensitivity, and sunburn can occur unusually easily. Avoid the sun at midday, wear covering clothes and sunglasses, and use sunscreen with a protection factor of at least 30 regularly. This also applies for a period after treatment ends.
- Constipation is the most common side effect (%34–42). Managing it proactively with plenty of fluids, a fiber-rich diet and, if necessary, a stool softener recommended by your physician is easier than treating it afterward.
- Unexplained muscle pain, weakness or dark urine must be reported—elevated CPK should be investigated.
- If your pulse slows (dizziness, weakness or feeling faint), report it; be sure to mention any other drugs you take that slow the heart rate.
- For new-onset cough, shortness of breath or fever, seek care promptly—if lung inflammation occurs at any grade, the drug is permanently discontinued.
Pregnancy and Contraception — Pay Attention to the Time Periods. Alectinib can harm an unborn baby. According to current product information: for women, during treatment and for at least 5 weeks after the last dose, for men with partners of childbearing potential, during treatment and for at least 3 months after the last dose effective contraception is required. Breastfeeding should be avoided during treatment. Online information such as “6 months for both sexes” or “3 months for women” is outdated.
Let Us Correct a Common Misconception. Some patient information texts circulating about alectinib include warnings such as “you may be susceptible to infections; avoid crowds” and “do not touch the medication with your hands; wear gloves.” These are warnings for conventional chemotherapy and do not apply to alectinib. Alectinib does not cause significant neutropenia and does not require the contact precautions used for cytotoxic drugs. Such generic texts create unnecessary anxiety for patients. The actual precautions for alectinib are those listed above: taking it with food, sun protection, constipation, muscle pain and liver tests.
Resistance: What Happens After Alectinib?
| Mechanism | Frequency | Meaning |
|---|---|---|
| ALK resistance mutation | Of resistant cases, %63–67 | Among these, G1202R ≈%37, I1171 series ≈%26, L1196M ≈%22, V1180L ≈%11 |
| MET gene amplification | In tissue biopsies ≈%15 | An ALK-independent escape pathway; combinations of an ALK inhibitor + MET inhibitor are being investigated |
| Activation of the NRG1–HER3–EGFR axis | Frequency could not be verified | Another ALK-independent escape pathway |
| NF2 alterations | Frequency could not be verified | Associated with early resistance to first-line alectinib |
The practical implication of this table is that performing a repeat biopsy (tissue or liquid) at progression after alectinib directly changes treatment selection. If two-thirds of resistance arises from ALK mutations, the next ALK inhibitor is logical; but if MET amplification is present, changing the ALK inhibitor will not work. G1202R is the most common mutation, explaining why lorlatinib is a logical choice after alectinib—it is a drug capable of overcoming this mutation.
| Option | Status |
|---|---|
| Lorlatinib | The most frequently preferred subsequent ALK inhibitor; covers most single mutations, including G1202R, and provides strong brain protection. We could not verify specific response and survival figures after alectinib |
| Brigatinib | In the J-ALTA study after alectinib, response rate %34, median progression-free survival ≈7 months (n=47) |
| Neladalkib (NVL-655) | Fourth-generation; under FDA priority review, with a decision date of 27 November 2026. Not authorized in Turkey |
| Platinum + pemetrexed chemotherapy | When ALK inhibitor options are exhausted; continuing the TKI if brain disease is present |
A Critical Restriction Specific to Turkey: According to the SGK text, in patients who progress after alectinib, sequential crizotinib, brigatinib and ceritinib are not covered. Lorlatinib is not included in this prohibited list; indeed, lorlatinib’s own reimbursement condition explicitly includes patients “who developed progression while previously treated with alectinib.” Thus, the anticipated pathway after alectinib in Turkey is through lorlatinib. This also aligns with international practice.
Alectinib or Lorlatinib? First-Line Selection
Guidelines list all three—alectinib, lorlatinib and brigatinib—among preferred first-line options. No randomized trial directly compares them; the following table is compiled from two separate trials and is not a direct comparison.
| Alectinib | Lorlatinib | |
|---|---|---|
| First-line trial | ALEX (versus crizotinib) | CROWN (versus crizotinib) |
| Median progression-free survival | 34,8 months | Not reached; at 7 years %55 progression-free |
| Progression-free survival hazard ratio | 0,43 | 0,19 |
| Brain protection | Strong | Stronger (intracranial progression HR 0,06) |
| Median overall survival | 81,1 months (not significant, HR 0,78) | Immature |
| Postoperative (adjuvant) approval | YES | NO |
| Predominant side effects | Constipation, muscle pain, elevated liver tests and CPK, photosensitivity | Elevated blood lipids, cognitive and mood effects, edema, weight gain |
| Cognitive side effects | None | Approximately %30 (severe %5) |
| Dosing schedule | 2 times daily, with food | 1 time daily, with or without food |
Practical Framework: Lorlatinib’s progression-free survival and brain protection figures are stronger—indirect comparisons also point in this direction. Alectinib, however, has a milder side-effect profile and does not have a pattern of cognitive effects; this may be decisive for working patients whose mental performance is critical to their profession. In surgically treated early-stage disease, there is no choice: alectinib is the only drug approved in that setting. The decision is made together, considering brain metastases, the patient’s occupation and daily life, blood lipids and liver status, preference for once- or twice-daily dosing, and reimbursement conditions.
Frequently Asked Questions
- I Had Surgery and the Tumor Was Completely Removed. Why Do I Still Need Medication?
- Because microscopic cells invisible to the eye may remain, and ALK-positive disease carries a high recurrence risk. In the ALINA trial, 2 years of alectinib significantly reduced the risk of recurrence or death: at the fourth year, the disease-free proportions were %75,5 versus %47,0 . The proportion without brain recurrence was also %90,4 versus %76,1—because chemotherapy cannot penetrate the brain, this difference is biologically expected.
- How Long Will Adjuvant Treatment Last?
- Up to 2 years. This duration was established in the study; treatment is stopped earlier if intolerable side effects or recurrence occur. In metastatic disease, the duration is not predetermined; treatment continues until the disease progresses.
- Does Alectinib Prevent Recurrence or Postpone It?
- This is the most honest question in the field, and the answer is not yet certain. The hazard ratio was 0,24 in the initial analysis and rose to 0,35 with four-year follow-up—meaning some patients develop late recurrence after treatment ends. The four-year difference remains large (%75,5 versus %47,0), but how the curves will behave with longer follow-up is unknown. Overall survival is also still immature.
- Must the Drug Be Taken with Food?
- Yes; this is not optional. Alectinib’s oral absorption is approximately %37, and when taken with a high-fat meal, blood levels can rise up to threefold. If you take it on an empty stomach, you will not receive the correct dose. Take it in the morning and evening with a meal, approximately 12 hours apart.
- My Liver Tests and Bilirubin Have Increased. Will We Stop the Drug?
- Not necessarily. These elevations are very common with this drug (AST %50–75, bilirubin %54–68), and the vast majority are mild. Specific thresholds guide dose adjustments. One important detail: elevated bilirubin does not always originate from the liver —alectinib can cause red blood cell breakdown (hemolytic anemia) in approximately %3 of patients, which also increases bilirubin. Treatment should not be stopped without making this distinction.
- I Have Muscle Pain. Is That Normal?
- Muscle pain is a common side effect of this drug (%23–34) and is usually mild. However, if pain is significant, you have weakness or your urine becomes dark, be sure to report it —the muscle enzyme CPK should be measured. Elevated CPK is very common as a laboratory finding (%37–77), and treatment needs to be interrupted above certain thresholds.
- Can I Go Out in the Sun?
- Yes, provided you are careful. Alectinib causes photosensitivity, and sunburn can occur unusually easily. Avoid direct midday sunlight, wear covering clothes and sunglasses, and use sunscreen with a protection factor of at least 30 regularly. This precaution should continue for a period after treatment ends.
- Will This Drug Weaken My Immune System? Should I Avoid Crowds?
- No. Alectinib is not chemotherapy and does not cause significant neutropenia (a reduction in defense cells). Warnings online such as “you may be susceptible to infections” and “do not touch the drug with your hands” apply to conventional chemotherapy, not this drug. Anemia may occur, but that is a different condition. You can continue your normal social life.
- I Have Developed Shortness of Breath and Cough. What Should I Do?
- Seek care promptly. Alectinib can rarely (%1,7) cause lung inflammation, and the rule for this drug is clear: if lung inflammation is detected at any grade, permanently discontinue the drug. There is no option to “continue if it is mild.” Early reporting is therefore important.
- Will the Drug Be Less Effective if the Dose Is Reduced?
- Dose reduction is routine with this drug, occurring in approximately one-quarter of patients. The steps are 600 mg × 2 → 450 mg × 2 → 300 mg × 2. What matters is staying on treatment at a tolerable dose rather than stopping the drug entirely—indeed, in ALINA, the rate of complete discontinuation due to side effects was only %5 (compared with %13 in the chemotherapy arm).
- Does SGK Cover It in Turkey?
- Yes, for advanced disease—if ALK positivity has been confirmed by FISH testing in an accredited laboratory , coverage is provided until progression in first-line treatment and in patients progressing after crizotinib. Note two points: the reimbursement text accepts only FISH for ALK positivity, whereas the authorization text also accepts NGS and immunohistochemistry; and the reimbursement text available to us does not include postoperative adjuvant use. Have your treatment team confirm the current situation.
- What Is Used if Progression Occurs After Alectinib?
- The anticipated pathway in Turkey is lorlatinib; its reimbursement condition explicitly includes patients “who developed progression while previously receiving alectinib.” Under the SGK text, sequential crizotinib, brigatinib and ceritinib after alectinib are not covered. At progression, a repeat biopsy is also important: two-thirds of resistance arises from ALK mutations (most commonly G1202R), but approximately %15 involve MET gene amplification, in which case changing the ALK inhibitor will not work.
- Is Alectinib or Lorlatinib Better?
- There is no randomized trial directly comparing them; guidelines list both, along with brigatinib, among preferred first-line options. Lorlatinib has stronger figures for delaying progression and protecting the brain; alectinib has a milder side-effect profile and no pattern of cognitive effects. In surgically treated early-stage disease, however, there is no choice: alectinib is the only drug approved in that setting.
- I Am Thinking of Having a Child. How Long Should I Use Contraception?
- According to current product information, for women, during treatment and for at least 5 weeks after the last dose, for men with partners of childbearing potential, during treatment and for at least 3 months after the last dose effective contraception is required. Breastfeeding should be avoided during treatment. Periods such as “6 months” circulating online are outdated; nevertheless, consult your physician for your own situation.
Glossary
- ALK (anaplastic lymphoma kinase)
- An enzyme that governs cell growth. In a small proportion of lung cancers, this gene joins another gene and produces a growth signal that remains permanently switched on.
- Fusion / rearrangement
- The joining of two genes following a chromosome break. In ALK-positive lung cancer, its most common partner is the EML4 gene.
- Adjuvant treatment
- Treatment given after complete surgical removal of the tumor to prevent recurrence from residual cells invisible to the eye.
- Disease-free survival (DFS)
- The time after surgery until the disease returns. This is the main measure in adjuvant studies.
- Progression-free survival (PFS)
- In metastatic disease, the time from starting treatment until the tumor begins to grow on imaging.
- Overall survival (OS)
- The patient’s total survival time. It is not yet mature in either alectinib trial.
- Hazard ratio (HR)
- A number comparing two groups. 1,00 means “no difference”; 0,24 indicates that risk falls to approximately one-quarter. It is interpreted together with the confidence interval.
- Crossover
- Patients in the control arm receiving the study drug after progression. In ALEX, %25,2 of the crizotinib arm later switched to alectinib; this erases the overall survival difference.
- Active metabolite (M4)
- The substance into which alectinib is converted in the liver, with potency similar to the parent molecule. The drug’s effect is the sum of both.
- CPK (creatine phosphokinase)
- An enzyme found in muscle cells. Elevated blood levels indicate muscle damage; this is very common with alectinib and requires dose adjustment at specific thresholds.
- Hemolytic anemia
- Anemia caused by red blood cell breakdown. It may occur in approximately %3 of alectinib users and can be a nonhepatic cause of elevated bilirubin.
- Bradycardia
- A heart rate below normal. With alectinib, it occurs in approximately %11–12 of patients and is usually mild.
- Interstitial lung disease (ILD) / pneumonitis
- Drug-induced inflammation of lung tissue. It is uncommon (%1,7), but with alectinib, detection at any grade requires permanent discontinuation.
- Photosensitivity
- Sensitivity to light; sunburn developing unusually easily. A known and preventable side effect of alectinib.
- G1202R
- A mutation in the ALK gene’s “solvent front” region, the most common cause of resistance to second-generation ALK inhibitors, including alectinib. It occurs in approximately %37 of resistant cases after alectinib.
- MET amplification
- An increase in MET gene copy number. This is an ALK-independent escape pathway; changing the ALK inhibitor is not a solution in this situation.
- FISH / RT-PCR / NGS / immunohistochemistry
- Four separate laboratory methods demonstrating ALK positivity. In Turkey, the authorization text accepts all four, whereas the reimbursement text accepts only FISH.
- KÜB (Summary of Product Characteristics)
- A drug’s official information text in Turkey. It is the only reliable source for authorization status; it is searched at titck.gov.tr/kubkt by active ingredient name.
DROZDOGAN Academy Commentary
Alectinib is the only drug with a role in both early- and advanced-stage ALK-positive lung cancer. This gives it a special position within its class—but does not mean it is the most powerful drug. It is important to distinguish the two.
⚡ Why This Drug Matters
ALINA is the first phase 3 trial showing that targeted therapy works in surgically treated ALK-positive lung cancer, with a hazard ratio of 0,24, a magnitude rarely seen in adjuvant oncology. Moreover, two years of tablets proved both more effective and easier to tolerate than four cycles of chemotherapy—the rate of discontinuation due to side effects was %5 versus %13. The brain data are also strong: at the fourth year, the proportion without brain recurrence was %90,4 versus %76,1.
✅ Strengths
In metastatic disease, median progression-free survival is 34,8 months, median response duration 42,3 months and median overall survival 81,1 months—approximately seven years. The side-effect profile is manageable, and there is no pattern of cognitive effects, a real advantage for working patients. The packaging in Turkey is also rational: 224 capsules cover exactly 28 days at the standard dose, without leftovers or shortages.
⚠️ Limitations and Points Requiring Attention
In ALEX, the overall survival difference appears to be 27 months, but it is not statistically significant (HR 0,78; p=0,132)—because one-quarter of the crizotinib arm later switched to alectinib. In ALINA, the hazard ratio also rose with longer follow-up from 0,24 to 0,35; it is not yet clear whether recurrence is prevented or postponed, and overall survival is immature. Lorlatinib gives stronger figures for progression-free survival. There is also a gap in Turkey: for ALK positivity, the reimbursement text accepts only FISH , and the text available to us does not include adjuvant use.
🩺 What Should Be Done in Practice?
1. Ensure the drug is always taken with food —absorption drops markedly on an empty stomach; this is a dosing issue, not a preference.
2. Treat sun protection as part of treatment; photosensitivity is real and preventable.
3. Manage constipation proactively; it is the most common side effect and is difficult to treat afterward.
4. When bilirubin rises, do not automatically attribute it to the liver— exclude hemolytic anemia.
5. For unexplained muscle pain and weakness, measure CPK.
6. For lung inflammation, the rule is clear: if detected at any grade, permanently discontinue the drug.
7. Contraception periods: women 5 weeks, men 3 months —the online “6 months” information is outdated.
8. Do not apply generic chemotherapy warnings (fear of infection, prohibition on handling) to this drug; they create unnecessary anxiety for patients.
9. At progression, perform a repeat biopsy ; if MET amplification is present, changing the ALK inhibitor will not work.
❓ Questions Still Unanswered
Does adjuvant alectinib prevent recurrence or postpone it by two years? The shift in hazard ratio from 0,24 to 0,35 keeps this question open, and only longer follow-up will provide the answer. Is two years the correct duration, or should it be longer? Will residual DNA in the blood after surgery allow treatment to be shortened or extended? Alectinib or lorlatinib first-line? There is no direct comparison trial and probably never will be. And the question specific to Turkey: when will reimbursement for the adjuvant indication become clear?
Our Brief Verdict: In surgically treated ALK-positive lung cancer, alectinib currently has no alternative—it is the only targeted therapy approved in this setting, and its data are strong. In metastatic first-line treatment, it is a good option but not the only one; lorlatinib has stronger figures for delaying progression, while alectinib has a milder impact on everyday life. The choice balances the drug’s power against the patient’s life.
Transparency Note. ALINA’s initial analysis is based on the New England Journal of Medicine 2024 publication, and its 4-year update on the ESMO 2025 presentation (abstract 1787MO); we could not access the full text of the update, the figures were taken from conference reporting, and no p value was reported for the 4-year analysis. ALEX’s final overall survival data are based on the ESMO 2025 presentation file; the peer-reviewed article text could not be accessed. Percentages in the side-effect tables come from different sources and definitions: ALINA and ALEX rates are from United States product information tables, whereas rates of lung inflammation (%1,7) and hemolytic anemia (%3,1) are from the European product information’s pooled safety data—not just these two trials. We could not separately verify ALINA-specific rates of photosensitivity, ILD and hemolytic anemia. In ALINA, elevated CPK appears as a laboratory finding at %77 and as a reported adverse event at %43; this is not a contradiction but two different measurement methods.
Turkey Information: During preparation of this article, titck.gov.tr could not be accessed; the indication text was taken from a third-party mirror of the Summary of Product Characteristics, and the authorization date and number were not included because they could not be verified. Price information was obtained from two independent Turkish drug-price sources reflecting the weekly official price list; the primary list could not be accessed directly. Cycle cost calculations are our own, not official pricing; the figures given here are the drug’s listed price, not the amount paid by the patient. The reimbursement text is based on the source available to us, and SUT rules change frequently; reimbursement coverage of the adjuvant indication must be confirmed separately.
Other Items That Could Not Be Verified: The final survival figures from J-ALEX; specific response and survival figures for lorlatinib after alectinib; response rates for neladalkib; the frequency of NRG1–HER3–EGFR axis activation and NF2 alterations in resistance; exact guideline category ratings. The alectinib–lorlatinib comparison table is compiled from two separate trials and is not a direct comparison; no randomized trial compares them. This text is for information and does not replace diagnostic or treatment decisions.
References
- Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer (ALINA). N Engl J Med. 2024;390:1265-1276. NCT03456076.
- ALINA 4-year update. ESMO 2025, abstract 1787MO.
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (ALEX). N Engl J Med. 2017;377:829-838. NCT02075840.
- Mok T, et al. ALEX: final overall survival and safety analysis. ESMO 2025; Ann Oncol. 2025.
- Camidge DR, et al. Updated efficacy and safety data from the ALEX study. Ann Oncol. 2020.
- ALECENSA (alectinib) United States product information, Genentech. FDA approval 208434/S-015, 18 April 2024.
- ALECENSA (alectinib) European product information (SmPC), European Medicines Agency (EMA).
- Republic of Turkey Ministry of Health, Turkish Medicines and Medical Devices Agency — Summary of Product Characteristics and Package Leaflet database. titck.gov.tr/kubkt
- Republic of Turkey Ministry of Health drug price list, 2026.
- Social Security Institution Healthcare Implementation Communiqué — list of reimbursable drugs and principles of use.
- Review of ALK inhibitor resistance mechanisms — plasma and tissue genotyping series.
- J-ALTA study: brigatinib after alectinib in ALK-positive NSCLC.
- ALKOVE-1 study: neladalkib (NVL-655) in TKI-pretreated ALK-positive NSCLC.
Sources
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer.
N Engl J Med 2017.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.